이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

비호지킨 림프종을 앓고 있는 성인 참가자의 부작용, 질병 활동 변화 및 정맥 주사된 ABBV-291이 신체를 통해 이동하는 방식을 평가하기 위한 연구

2026년 9월 25일 업데이트: AbbVie

비호지킨 림프종에 대한 ABBV-291의 안전성, 약동학 및 효능을 평가하는 최초의 인간 대상 연구

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R) NHL, including but not limited to diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Adverse events will be assessed.

ABBV-291 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-291 and a dose expansion/optimization phase to determine the change in disease activity in participants with R/R NHL. Approximately 165 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide

In the dose escalation phase of the study participants will receive escalating Intravenously (IV) infused doses of ABBV-291, until the MAD/MTD is determined. In the dose expansion/optimization phase of the study participants receive IV infused ABBV-291, as part of the approximately 74 month study duration.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.

연구 개요

상태

모집하지 않고 적극적으로

개입 / 치료

연구 유형

중재적

등록 (실제)

21

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • North Carolina
      • Huntersville, North Carolina, 미국, 28078
        • Carolina BioOncology Institute /ID# 265259
    • Oregon
      • Eugene, Oregon, 미국, 97401
        • Willamette Valley Cancer Institute and Research Center /ID# 270945
    • Texas
      • Austin, Texas, 미국, 78705
        • Texas Oncology - Central/South Texas /ID# 270946
    • Utah
      • West Valley City, Utah, 미국, 84119-3602
        • START Mountain Region /ID# 267592
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • Virginia Cancer Specialists - Fairfax /ID# 265082
      • Manchester, 영국, M20 4BX
        • The Christie /ID# 267177
      • Plymouth, 영국, PL6 5FP
        • University Hospitals Plymouth NHS Trust /ID# 267174
    • Jerusalem
      • Jerusalem, Jerusalem, 이스라엘, 91120
        • Hadassah Medical Center-Hebrew University /ID# 261658
    • Tel Aviv
      • Tel Aviv, Tel Aviv, 이스라엘, 6423906
        • Tel Aviv Sourasky Medical Center /ID# 261659
    • Aichi-ken
      • Nagoya, Aichi-ken, 일본, 464-8681
        • Aichi Cancer Center /ID# 267471
    • Chiba
      • Kashiwa-shi, Chiba, 일본, 277-8577
        • National Cancer Center Hospital East /ID# 261775
    • Tokyo
      • Koto-ku, Tokyo, 일본, 135-8550
        • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 267470
    • Victoria
      • Fitzroy Melbourne, Victoria, 호주, 3065
        • St Vincent's Hospital Melbourne /ID# 261664
    • Western Australia
      • Nedlands, Western Australia, 호주, 6009
        • Sir Charles Gairdner Hospital /ID# 268579

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • For dose escalation (Part 1) only: Participants must have documented diagnosis of B-cell malignancies including (but not limited to) the following, with histology based on criteria established by the World Health Organization (WHO), and measurable disease requiring treatment:

    • Mantle cell lymphoma (MCL);
    • Marginal zone lymphoma (MZL);
    • Waldenstrom macroglobulinemia (WM);
    • Diffuse large b-cell lymphoma (DLBCL) (including: germinal center B-cell type, activated B-cell type, primary cutaneous DLBCL [leg type], Epstein-Barr virus-positive (EBV+) DLBCL [not otherwise specified], DLBCL associated with chronic inflammation, human herpesvirus 8-positive [HHV8+] DLBCL [not otherwise specified], B cell lymphoma [unclassifiable] with features intermediate between DLBCL and classical Hodgkin lymphoma, high-grade B-cell lymphoma [not otherwise specified], high-grade B-cell lymphoma [with MYC (avian myelocytomatosis viral oncogene homolog) and BCL2 and/or BCL6 rearrangements], DLBCL arising from follicular lymphoma [FL] [transformed FL]);
    • FL Grades 1 to 3B;
  • For dose expansion (Part 2) only: Participants must have documented diagnosis of one of the following B-cell malignancies, with histology based on criteria established by the WHO, and measurable disease requiring treatment:

    • Part 2a only: DLBCL (including: germinal center B-cell type, activated B-cell type, primary cutaneous DLBCL [leg type], EBV+ DLBCL [not otherwise specified], DLBCL associated with chronic inflammation, HHV8+ DLBCL [not otherwise specified], B-cell lymphoma [unclassifiable] with features intermediate between DLBCL and classical Hodgkin lymphoma, high-grade B-cell lymphoma [not otherwise specified], high-grade B-cell lymphoma [with MYC and BCL2 and/or BCL6 rearrangements], DLBCL arising from FL [transformed FL]);
    • Part 2b only: FL Grades 1 to 3B;
    • Part 2c only: Mantle cell lymphoma;
  • For all participants (Parts 1 and 2):

    • Must be considered relapsed or refractory to, or intolerant of, at least 2 or more prior lines of therapy known to provide a clinical benefit for their condition, and for whom there is no appropriate locally available therapy known to provide clinical benefit (e.g., standard chemotherapy or autologous stem cell transplantation [ASCT]).

    • Indolent non-Hodkin's lymphoma (NHL) participants must meet relevant disease specific requirements for treatment (e.g., National Comprehensive Cancer Network [NCCN], Groupe d'Etude des Lymphomes Folliculaires [GELF]).

    • History of allogeneic stem cell transplantation must be stable off of immunosuppression for at least 3 months.

    • For participants enrolled in backfill cohorts or at dose levels previously cleared, subjects must provide consent to an on-treatment fresh tumor biopsy from the same tumor lesion as the baseline tumor tissue. This requirement may be waived at the discretion of the contract research organization (CRO) Medical Monitor if collecting a biopsy would place the subject at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a subject's ability to participate in the study.

    • Previously treated with a CD79b-targeting therapy (e.g., CD79b monoclonal antibody) a core or excision tumor biopsy subsequent to the most recent CD79b-targeting therapy must be collected. Tumor biopsy requirements may be modified by Sponsor during the study. This requirement may be waived at the discretion of the contract research organization (CRO) Medical Monitor if collecting a biopsy would place the subject at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a subject's ability to participate in the study.

      • CD79b expression status will be assessed in all participants.
  • Have an eastern cooperative oncology group (ECOG) Performance Status of 0 or 1.

  • Laboratory values meeting the criteria in the protocol within the screening period prior to the first dose of study drug (if multiple samples are drawn within the screening period, the sample/result immediately prior to Cycle 1 Day 1 is applicable).

  • Availability of representative baseline tumor tissue (most recent archived tumor tissue or fresh biopsy collected during screening phase) suitable for immunohistochemistry (IHC) testing. This requirement may be waived at the discretion of the CRO Medical Monitor if collecting a biopsy at screening would place the participant at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a participant's ability to participate in the study.

Exclusion Criteria:

  • History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis.

  • Treatment with any of the following:

    • Anticancer therapy including chemotherapy, radiotherapy, small molecule, investigational, and biologic agents within 14 days (or at least 5 half-lives, whichever is shorter), prior to the first dose of the study treatment;
    • CD79b-directed agents (e.g., CD79b monoclonal antibody therapy) within 4 weeks (or at least 5 half-lives, whichever is shorter) prior to the first dose of study treatment.
    • Prior treatment with an antibody drug conjugate that consists of a topoisomerase I inhibitor.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Escalation: Non-Hodgkin Lymphoma (NHL) ABBV-291

Participants with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), except chronic lymphocytic leukemia (CLL), will receive escalating doses of ABBV-291, as part of the 74 month study duration.

Intravenous Infusion

실험적: Expansion: Diffuse Large B-Cell Lymphoma (DLBCL) ABBV-291

Participants with R/R DLBCL will receive the recommended Phase 1 expansion dose (RP1ED) of ABBV-291, as part of the 74 month study duration.

Intravenous Infusion

실험적: Expansion: Follicular Lymphoma (FL) ABBV-291

Participants with R/R FL will receive the RP1ED of ABBV-291, as part of the 74 month study duration.

Intravenous Infusion

실험적: Optimization: Mantle Cell Lymphoma (MCL) ABBV-291 Dose A

Participants with R/R MCL will receive the dose A of ABBV-291, as part of the 74 month study duration.

Intravenous Infusion

실험적: Optimization: MCL ABBV-291 Dose B

Participants with R/R MCL will receive the dose B of ABBV-291, as part of the 74 month study duration.

Intravenous Infusion

실험적: Optimization: MCL ABBV-291 Dose C

Participants with R/R MCL will receive the dose C of ABBV-291, as part of the 74 month study duration.

Intravenous Infusion

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants with Adverse Events (AE)s
기간: Up to 74 Months

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.

Up to 74 Months
Percentage of Participants with Dose Limiting Toxicities (DLT)s
기간: Up to 74 Months

DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

Up to 74 Months
Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, and Hematology)
기간: Up to 74 Months

Percentage of participants with clinically significant laboratory values (chemistry, and hematology).

Up to 74 Months
Percentage of Participants with Clinically Significant Vital Sign Measurements
기간: Up to 74 Months

Vital sign are defined as determinations of systolic and diastolic blood pressure, pulse rate, respiratory rate, and body temperature.

Up to 74 Months
Percentage of Participants with Clinically Significant Electrocardiogram (ECG) Findings
기간: Up to 74 Months

Percentage of participants with clinically significant ECG findings.

Up to 74 Months
Objective Response Rate (ORR)
기간: Up to 74 Months

ORR is defined as the percentage of participants with a confirmed best overall response (BOR) of partial response (PR) or better per disease-specific response criteria (e.g., Lugano classification).

Up to 74 Months

2차 결과 측정

결과 측정
측정값 설명
기간
Duration of Response (DOR) as Assessed by Investigator
기간: Up to 74 Months

DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to disease-specific response criteria to disease progression or death of any cause, whichever occurs earlier.

Up to 74 Months
Progression-Free Survival (PFS) as Assessed by Investigator
기간: Up to 74 Months

PFS is defined as time from first study treatment to a documented disease progression according to disease-specific response criteria, as determined by the investigator, or death due to any cause, whichever occurs earlier.

Up to 74 Months
Time to response (TTR)
기간: Up to 74 Months

TTR is defined as time from first study treatment to the initial response of PR (or better) per investigator review according to disease-specific response criteria.

Up to 74 Months
Area Under the Curve (AUC) of ABBV-291
기간: Up to 12 Months

AUC is defined as the area under the plasma/serum concentration-time curve of ABBV-291.

Up to 12 Months
Maximum Observed Plasma/Serum Concentration (Cmax) of ABBV-291
기간: Up to 12 Months

Cmax is defined as maximum observed plasma/serum concentration of ABBV-291.

Up to 12 Months
Time to Cmax (Tmax) of ABBV-291
기간: Up to 12 Months

Tmax is defined as time to Cmax of ABBV-291.

Up to 12 Months
Half-Life (t1/2) of ABBV-291
기간: Up to 12 Months

t1/2 is defined as the half-life of ABBV-291.

Up to 12 Months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: ABBVIE INC., AbbVie

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 1월 16일

기본 완료 (추정된)

2027년 1월 1일

연구 완료 (추정된)

2031년 11월 1일

연구 등록 날짜

최초 제출

2024년 10월 30일

QC 기준을 충족하는 최초 제출

2024년 10월 30일

처음 게시됨 (실제)

2024년 10월 31일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 29일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 25일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다